Compare Select Medical Holdings Corporation (SEM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Select Medical Holdings Corporation vs Sanofi SA — how do they compare? Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 51.1× Select Medical Holdings Corporation's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SEM | SNY | |
|---|---|---|
Market Cap | $2.05B | $104.83B |
Sector | Health | Health |
52-Week High | $16.66 | $52.34 |
52-Week Low | $11.77 | $41.33 |
Enterprise Value | $5.01B | $121.32B |
Dividend Yield | 1.51% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Select Medical (SEM) trades at $16.51, unchanged on the day, amid a completed acquisition by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share. The stock shows a bullish technical signal with support and resistance clustered around $17. Financially, the company reported 2025 revenue of $5.45B and net income of $146.22M, with a P/E of 15.43 and P/S of 0.36 indicating moderate valuation. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026.
The acquisition at $16.50 per share caps near-term upside, with legal investigations into the board's fiduciary duties posing a key risk. Analyst sentiment is mixed with 35.71% buy ratings but 57.15% hold, reflecting uncertainty post-buyout. Investors should note the stock's limited movement potential given the acquisition price, with fundamental performance and legal outcomes driving any residual value.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
